Blood test could predict immunotherapy success in lung cancer

NCT ID NCT05426668

Recruiting now Diagnosis Sponsor: Karsten Gavenis Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 24 times

Summary

This study is testing a new blood test called TheraSure CNI-Monitor for people with advanced lung cancer (NSCLC) who are receiving immunotherapy. The test looks for tiny bits of tumor DNA in the blood to see if the cancer is responding to treatment. Researchers want to know if the test can predict treatment failure earlier than standard scans, helping doctors make better decisions. About 170 participants will be enrolled across three centers in Germany.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Medizinische Hochschule Hannover
RECRUITING

Hanover, 30625, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
Pius-Hospital Oldenburg
RECRUITING

Oldenburg, 26121, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Medical Center Göttingen
RECRUITING

Göttingen, Lower Saxony, 37075, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC